Lantern Pharma. has filed a patent for illudin derivatives, offering new synthetic routes and compounds with therapeutic potential. The process involves synthesizing compounds with a specific formula, opening up possibilities for novel pharmaceutical compositions. GlobalData’s report on Lantern Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Lantern Pharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Lantern Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Lantern Pharma's grant share as of January 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.

Synthesizing illudin derivatives for therapeutic purposes

Source: United States Patent and Trademark Office (USPTO). Credit: Lantern Pharma Inc

The patent application (Publication Number: US20230399285A1) discloses a process for synthesizing compounds with a specific chemical formula. The method involves various steps, including selecting a cyclopentenone, protecting the alcohol group, reacting with a diazoketone, reducing the cycloadduct, alkylating a ketone group, cleaving an oxy group, and oxidizing to obtain the desired compound. The process also includes isolating the final product using standard purification techniques. Additionally, the patent claims methods for synthesizing enantiopure acylfulvene, hydroxymethyl acylfulvene (HMAF), and hydroxyureamethylacylfulvene (UMAF) through enzymatic resolution of a specific compound.

Furthermore, the patent application details specific variations and options within the process, such as selecting substituted or unsubstituted cyclopentenones, using different protecting groups like acetyl or benzyl, and employing alkylating agents such as alkyl halides. The method also specifies the use of suitable reagents for cleaving the oxy group and achieving the desired chemical reactions. The application emphasizes the importance of isolating the final product, hydroxyureamethylacylfulvene (+), through standard purification techniques. Overall, the patent application provides a detailed and specific process for synthesizing compounds with the defined chemical formula, offering variations and options for optimizing the synthesis process.

To know more about GlobalData’s detailed insights on Lantern Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies